- TRADE NAME: Darzalex (Janssen Biotech)
- INDICATIONS: Multiple myeloma in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent
- CLASS: Monoclonal antibody
- HALF-LIFE: 18 days
- FDA APPROVAL DATE: 11/16/2015
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: No data available
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see two reviews of daratumumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 04/12/2024
